AnaCardio

CompanySweden

AnaCardio develops one asset, in phase 2 (AC01 in heart failure with reduced ejection fraction). Mostly small molecule; based in Sweden.

1
Asset
Furthest stage
Phase 2
Raised
$89.9M
2
Trials
2
Signals

Pipeline

1
  • AC01

    Activates the ghrelin receptor to enhance cardiac contractility.

    Phase 2, Small molecule, heart failure with reduced ejection fraction

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials2
  • Funding rounds and grants2
  • Signals5
  • Similar companies6

Intelligence